The investment of $3 million from Bradbury Asset Management is a positive development for IGC Pharma, indicating confidence in the company's future and its investigational medicine IGC-AD1. This influx of funds is likely to support the company's general corporate purposes and the advancement of its investigational medicines, potentially leading to positive developments in its pipeline. The fact that the shares are unregistered and not immediately tradable suggests a commitment from Bradbury Asset Management to a longer-term investment, which could be seen positively by the market. However, the impact on the stock price will also depend on market perception of the dilution caused by the issuance of new shares.